IL 206845 to BioMarin Pharmaceuticals Inc. was refused under Section 21a of the Israel Patent Law 1967. The patent application was the national phase of a PCT application submitted on 6 January 2009. The national phase entry was submitted on 6 July… Read More ›
This ruling concerns a product that resulting from the contributions of two people who were formerly friends. A patent application was filed that named both people as both inventors and applicants. Later, after powers-of-attorney signed by each of the named inventor – applicants had… Read More ›
IL 146954 to Genentech is titled “HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES”. It is the national phase of PCT/US2000/07366. The active ingredient is Pertezumab. Pertuzumab received US FDA approval for the treatment of HER2-positive metastatic breast cancer on… Read More ›
Yesterday I enjoyed a pleasant trip down South to attend the WIPO Roving Seminar in Beer Sheva. The drive was pleasant. Negev is very verdant and the ornithology was good, with a lot of storks and black kites and the odd… Read More ›
In an earlier post, I summarized the 2013 Patent Office Report. It is interesting to see what happens when journalists who are non-patent professionals analyze and report on the same data. Arutz 7 is a nationalist news web-site. It used… Read More ›
Worrying drop in PCT filings by Israelis, but what is the underlying reason?